摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-vinylthiophenol | 89664-22-2

中文名称
——
中文别名
——
英文名称
2-vinylthiophenol
英文别名
o-Vinylthiophenol;Benzenethiol, 2-ethenyl-;2-ethenylbenzenethiol
2-vinylthiophenol化学式
CAS
89664-22-2
化学式
C8H8S
mdl
MFCD18451581
分子量
136.218
InChiKey
NADUDFSNHZPLIN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    1
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

  • 作为产物:
    描述:
    alkaline earth salt of/the/ methylsulfuric acid 在 一氧化碳 作用下, 以 四氢呋喃 为溶剂, 20.0 ℃ 、506.62 kPa 条件下, 反应 3.0h, 生成 2-vinylthiophenol
    参考文献:
    名称:
    噻吩与过渡金属的均相反应:阐明加氢脱硫机理的建模方法和合成异常有机硫化合物的有效方法
    摘要:
    Ph$+ 选择性地攻击 CZ 碳原子以产生 [(triphos)Rh{v4-SCHCHCH(CH2CPh3)}]PF6 (S),其结构已通过 X 射线衍射确定。配合物 8 在正交空间群 P212121(编号 19)中结晶,a = 10.834(6) A,b = 15.012(6) A,c = 39.902(9) A,2 = 4,V = 6489.66 A3。阳离子 [(triphos)Rh(q4-SCHCHCH(CHZCPh3)}]+ 呈现扭曲的方形金字塔结构,一个 P 原子占据顶端位置,而其余两个 P 原子加上 C6-S 和 C7-C8 键占据基础位点;C8 原子带有三苯甲基取代基。乙烯基苯硫酚配合物 3 也在 CZ 处与 HBF4.OEt2 选择性质子化,生成 [(triphOS)Rh{v4-s(c61&)CH(CH3)}]BPb (9) , 3-三苯基亚丙基)环己二烯硫酮,并为顺式1
    DOI:
    10.1021/ja00120a015
点击查看最新优质反应信息

文献信息

  • SULFUR CHELATED RUTHENIUM COMPOUNDS USEFUL AS OLEFIN METATHESIS CATALYSTS
    申请人:Ben-Gurion University Of The Negev Research And Development Authority
    公开号:US20140155511A1
    公开(公告)日:2014-06-05
    Sulfur chelated ruthenium compounds represented by the following formula: wherein M indicates the ruthenium metal bound to a benzylidene carbon; R represents C 1 -C 7 alkyl group or optionally substituted aryl; X 1 and X 2 each independently represent halogen; Y 1 and Y 2 each independently denote unsubstituted or alkyl-substituted phenyl; and Z independently represents hydrogen, electron withdrawing or electron donating substituent, with m being an integer from 1 to 4, and processes and compositions related thereto.
    以下是由下列公式表示的硫螯合钌化合物:其中M表示与苯甲亚碳结合的钌金属;R代表C1-C7烷基或可选择取代的芳基;X1和X2分别独立表示卤素;Y1和Y2分别表示未取代或烷基取代的苯基;Z独立表示氢、电子吸引或电子给予取代基,其中m为1至4的整数,以及相关的过程和组合物。
  • Sulfur chelated ruthenium compounds useful as olefin metathesis catalysts
    申请人:Lemcoff Gabriel N.
    公开号:US20090156766A1
    公开(公告)日:2009-06-18
    Sulfur chelated ruthenium compounds and methods and compositions involving the same. A method may relate to subjecting an olefin to a metathesis reaction in the presence of a sulfur chelated ruthenium compound. A composition may relate to an olefin starting material dissolved in an organic solvent together with a sulfur chelated ruthenium compound.
    硫螯合钌化合物及涉及其的方法和组合物。一种方法可能涉及在存在硫螯合钌化合物的情况下使烯烃经历交换反应。一种组合物可能涉及将烯烃起始物溶解在有机溶剂中,与硫螯合钌化合物一起。
  • [EN] BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN<br/>[FR] DÉRIVÉS DE BENZYLAMINE EN TANT QU'INHIBITEURS DE KALLIKRÉINE DU PLASMA
    申请人:KALVISTA PHARMACEUTICALS LTD
    公开号:WO2013005045A1
    公开(公告)日:2013-01-10
    The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R9 are as defined herein.
    本发明提供了如下式(I)的化合物:包含这些化合物的组合物;在治疗中使用这些化合物(例如在涉及血浆激肽酶活性的疾病或症状的治疗或预防中);以及使用这些化合物治疗患者的方法;其中R1至R9如本文中所定义。
  • Carboxylic acid derivative and medicine comprising salt or ester of the same
    申请人:——
    公开号:US20040214888A1
    公开(公告)日:2004-10-28
    The present invention provides novel carboxylic acid derivatives useful as an insulin sensitizer, a salt thereof or a hydrate of them, and a medicament comprising the derivative as the active ingredient. Specifically, it provides a carboxylic acid derivative represented by the following formula: 1 (wherein L represents a single bond, or a C1 to C6 alkylene group, a C2 to C6 alkenylene group or a C2 to C6 alkynylene group, each of which may have one or more substituent groups; M represents a single bond, or a C1 to C6 alkylene group, a C2 to C6 alkenylene group or a C2 to C6 alkynylene group, each of which may have one or more substituent groups; T represents a single bond, or a C1 to C3 alkylene group, a C2 to C3 alkenylene group or a C2 to C3 alkynylene group, each of which may have one or more substituent groups; W represents a carboxyl group; X represents a single bond, an oxygen atom, or a group represented by the various substituent groups including —NR X1 CQ 1 O— (wherein Q 1 represents an oxygen atom or a sulfur atom; R X1 represents a hydrogen atom, a cyano group, a formyl group, or various groups including a C1 to C6 alkyl group and a C1 to C6 hydroxyalkyl group, each of which may have one or more substituent groups), ONR X1 CQ 1 —, —NR X1 CQ 1 —, —CQ 1 NR X1 —, —NR X1a CQ 1 NR X1b —, —Q 2 SO 2 — and —SO 2 Q 2 —; Y represents a 5 to 14-membered aromatic group which may have one or more substituent groups and one or more hetero atoms, or a C3 to C7 alicyclic hydrocarbon group; and the rings Z and U may be the same as or different from each other and each represents a 5 to 14-membered aromatic group which may have 1 to 4 substituent groups and one or more hetero atoms, and the ring may be partially saturated.), a salt thereof, an ester thereof or a hydrate of them.
    本发明提供了一种新型羧酸衍生物,可用作胰岛素增敏剂,其盐或其水合物,以及包含该衍生物作为活性成分的药物。具体而言,本发明提供了一种由以下式子表示的羧酸衍生物:1(其中L表示单键,或C1至C6烷基,C2至C6烯基或C2至C6炔基,每个基团都可以有一个或多个取代基;M表示单键,或C1至C6烷基,C2至C6烯基或C2至C6炔基,每个基团都可以有一个或多个取代基;T表示单键,或C1至C3烷基,C2至C3烯基或C2至C3炔基,每个基团都可以有一个或多个取代基;W表示羧基;X表示单键,氧原子,或由各种取代基表示的基团,包括-NRX1CQ1O-(其中Q1表示氧原子或硫原子;RX1表示氢原子,氰基,甲酰基或各种基团,包括C1至C6烷基和C1至C6羟基烷基,每个基团都可以有一个或多个取代基),ONRX1CQ1-,-NRX1CQ1-,-CQ1NRX1-,-NRX1aCQ1NRX1b-,-Q2SO2-和-SO2Q2-;Y表示一个具有1个或多个取代基和1个或多个杂原子的5至14环芳基,或一个C3至C7脂环烃基;环Z和环U可以相同或不同,每个环表示一个具有1至4个取代基和1个或多个杂原子的5至14环芳基,环可能部分饱和),其盐,酯或其水合物。
  • Carboxylic acid derivative and salt thereof
    申请人:——
    公开号:US20040102634A1
    公开(公告)日:2004-05-27
    The present invention provides a novel carboxylic acid compound, a salt thereof or a hydrate of them useful as an insulin sensitizer, and a medicament comprising the compound as an active ingredient. That is, the present invention provides a carboxylic acid compound represented by the following formula, a salt thereof, an ester thereof or a hydrate of them. 1 Wherein R 1 represents a hydrogen atom, hydroxyl group, halogen, carboxyl group, or a C 1-6 alkyl group etc., each of which may have one or more substituents; L represents a single bond, or a C 1-6 alkylene group, a C 2-6 alkenylene group or a C 2-6 alkynylene group, each of which may have one or more substituents; M represents a single bond, or a C 1-6 alkylene group, a C 2-6 alkenylene group or a C 2-6 alkynylene group, each of which may have one or more substituents; T represents a single bond, or a C 1-3 alkylene group, a C 2-3 alkenylene group or a C 2-3 alkynylene group, each of which may have one or more substituents; W represents a carboxyl group; 2 represents a single bond etc.; X represents a single bond, oxygen atom, a group represented by —NR X1 CQ 1 O— (wherein Q 1 represents an oxygen atom or sulfur atom; and R X1 represents a hydrogen atom, formyl group, or a C 1-6 alkyl group etc., each of which may have one or more substituents), —OCQ 1 NR X1 — (wherein Q 1 and R X1 are as defined above), —CQ 1 NR X1 O— (wherein Q 1 and R X1 are as defined above), ONR X1 CQ 1 — (wherein Q 1 and R X1 are as defined above), -Q 2 SO 2 — (wherein Q 2 is an oxygen atom or —NR X10 — (wherein R X10 represents a hydrogen atom, formyl group, or a C 1-6 alkyl group etc., each of which may have one or more substituents)) or —SO 2 Q 2 - (wherein Q 2 is as defined above), (wherein, provided that R X2 and R X3 , and/or R X4 and R X5 may together form a ring, Q 3 and Q 4 are the same as or different from each other and each represents an oxygen atom, (O)S(O) or NR X10 (wherein NR X10 is as defined above)); Y represents a 5- to 14-membered aromatic group etc., which may have one or more substituents and one or more hetero atoms; and the ring Z represents a 5- to 14-membered aromatic group which may have 0 to 4 substituents and one or more hetero atoms, and wherein part of the ring may be saturated.
    本发明提供了一种新型的羧酸化合物、其盐或水合物,作为胰岛素增敏剂,并且提供了一种包含该化合物作为活性成分的药物。即,本发明提供了由以下式表示的羧酸化合物、其盐、酯或水合物。其中,R1表示氢原子、羟基、卤素、羧基或C1-6烷基等,每个都可以有一个或多个取代基;L表示单键,或C1-6烷基、C2-6烯基或C2-6炔基等,每个都可以有一个或多个取代基;M表示单键,或C1-6烷基、C2-6烯基或C2-6炔基等,每个都可以有一个或多个取代基;T表示单键,或C1-3烷基、C2-3烯基或C2-3炔基等,每个都可以有一个或多个取代基;W表示羧基;2表示单键等;X表示单键、氧原子、由—NRX1CQ1O—表示的基团(其中,Q1表示氧原子或硫原子;RX1表示氢原子、甲酰基或C1-6烷基等,每个都可以有一个或多个取代基)、由—OCQ1NRX1—表示的基团(其中,Q1和RX1如上所定义)、由—CQ1NRX1O—表示的基团(其中,Q1和RX1如上所定义)、由ONRX1CQ1—表示的基团(其中,Q1和RX1如上所定义)、由-Q2SO2—表示的基团(其中,Q2是氧原子或—NRX10—(其中,RX10表示氢原子、甲酰基或C1-6烷基等,每个都可以有一个或多个取代基))或由—SO2Q2—表示的基团(其中,Q2如上所定义),(其中,假设RX2和RX3,以及RX4和RX5可以共同形成环,Q3和Q4相同或不同,每个表示氧原子、(O)S(O)或NRX10(其中,NRX10如上所定义));Y表示5-至14-成员芳香基等,可以有一个或多个取代基和一个或多个杂原子;环Z表示5-至14-成员芳香基,可以有0至4个取代基和一个或多个杂原子,其中环的一部分可以饱和。
查看更多